WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will present at two investor conferences next week. A live webcast of each presentation will be available through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay of each presentation will be available at the same location for one week.
